Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors-Reference-Cited by-同舟云学术

Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors

Published:2006-06-02 Issue:12 Volume:176 Page:7308-7316
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Purbhoo Marco A.,Sutton Deborah H.,Brewer Joanna E.,Mullings Rebecca E.,Hill Maxine E.,Mahon Tara M.,Karbach Julia,Jäger Elke,Cameron Brian J.,Lissin Nikolai,Vyas Paresh,Chen Ji-Li,Cerundolo Vincenzo,Jakobsen Bent K.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference44 articles.

1. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

2. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

3. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

4. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fast on-rates of chimeric antigen receptors enhance the sensitivity to peptide MHC via antigen rebinding;Journal of Biological Chemistry;2024-09

2. Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities;Science Translational Medicine;2024-07-10

3. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors;Journal for ImmunoTherapy of Cancer;2024-07

4. Dual role of the peptide-loading complex as proofreader and limiter of MHC-I presentation;Proceedings of the National Academy of Sciences;2024-05-21

5. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy;Biomedicines;2024-04-01